Perfil de la empresa para HilleVax, Inc. - Common Stock Acción
HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.
Obtén información actualizada de finAgent sobre HilleVax, Inc. - Common Stock